Press Releases

Date Title
Toggle Summary vTv Therapeutics Inc. Announces Launch of Initial Public Offering
vTv Therapeutics Inc. (the “Company”) today announced the launch of its initial public offering in the United States of 7,812,500 shares of its Class A common stock. The initial public offering price is currently expected to be between $15.00 and $17.00 per share of Class A common stock.  The
View HTML
Toggle Summary vTv Therapeutics Appoints Rudy Howard as Chief Financial Officer
High Point, North Carolina (June 29, 2015) vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced the appointment of Rudy C.
View HTML
Toggle Summary vTv Therapeutics Files Registration Statement for Proposed Initial Public Offering
High Point, North Carolina (June 15, 2015)   vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates, today announced it has filed a registration statement on Form S-1 with the U.S.
View HTML
Toggle Summary vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes
In a 6 Week Phase 2a Study, Treatment Showed Statistically Significant and Clinically Meaningful Reduction in A1c Levels High Point, North Carolina (June 4, 2015) vTv Therapeutics LLC announced today that it has initiated dosing of the AGATA study, a phase 2b clinical trial assessing the efficacy
View HTML
Toggle Summary vTv Therapeutics Initiates Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease
Completed Phase 2 Trial Showed Positive Results Combating Alzheimer’s Disease High Point, North Carolina (May 19, 2015) vTv Therapeutics LLC (vTv) today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy),
View HTML
Toggle Summary TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program
High Point, North Carolina (March 5, 2015) TransTech Pharma, LLC today announced a global licensing agreement granting Calithera Biosciences, Inc. exclusive world-wide rights to research, develop and commercialize TransTech’s portfolio of hexokinase II inhibitors.
View HTML
Toggle Summary TransTech Pharma, LLC Announces Agreement with FDA on Special Protocol Assessment for TTP488 Phase 3 Trial in Patients with Mild Alzheimer's Disease
High Point, North Carolina (July 10, 2014) TransTech Pharma, LLC today announced that it has reached an agreement with the U.S. Food and Drug Administration Division of Neurology Products, under the Special Protocol Assessment (SPA) process, on the design of a single Phase 3 trial of TTP488 for the
View HTML
Toggle Summary Stephen L. Holcombe Appointed President of TransTech Pharma and High Point Pharmaceuticals
High Point, North Carolina (April 15, 2014) TransTech Pharma, LLC (“TransTech”) announced today that effective March 28, 2014, Stephen L. Holcombe, who previously served as the Company’s Senior Vice President and Chief Financial Officer, has been appointed to serve as the President of TransTech and
View HTML
Toggle Summary First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial
High Point, North Carolina (August 14, 2013) TransTech Pharma Inc. announced today important clinical trial data for its new diabetes drug. TTP399, a novel, liver-selective glucokinase activator (GKA), demonstrated clinical evidence of normalizing HbA 1c without inducing hypoglycemia in type 2
View HTML
Toggle Summary TransTech Pharma Completes End of Phase 2 Meeting with FDA for TTP488
High Point, North Carolina (July 1, 2013) TransTech Pharma Inc. announced today that it has successfully completed an End of Phase 2 meeting for TTP488 with the U.S. Food and Drug Administration (FDA). TTP488 is under development for the treatment of mild to moderate Alzheimer’s disease.
View HTML